Compare Moderna, Inc. (MRNA) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs NICE Ltd — how do they compare? Moderna, Inc. trades at $136.11 (market cap $56.02B), while NICE Ltd trades at $98.12 (market cap $5.94B). The key difference: Moderna, Inc. is far larger — about 9.4× NICE Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| MRNA | NICE | |
|---|---|---|
Market Cap | $56.02B | $5.94B |
Sector | Health | Technology |
52-Week High | $174.38 | $153.44 |
52-Week Low | $22.36 | $83.15 |
Enterprise Value | $52.17B | $5.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
NICE stock trades at $101.47, down 3.82% in the last session, reflecting near-term bearish technical signals. The company maintains strong fundamentals with a P/E of 14.77 and robust profitability, including a 65.12% gross margin and consistent earnings beats in recent quarters. Recent news highlights AI platform deployments with major clients like AOK PLUS and Bluecrest, reinforcing growth in the CX segment. Analyst consensus remains positive with a $118.67 price target, though technical indicators suggest caution amid a bearish overall signal.
The outlook for NICE is supported by solid cloud and AI revenue growth, upward EPS guidance, and a debt-light balance sheet. Key risks include execution challenges in scaling AI offerings and competitive pressures in the customer engagement software market. With no sell ratings from analysts and institutional accumulation, the stock presents a value opportunity for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
